Physician profile
Mohammad Khan
NPI 1356673925
$562.63
in general payments reported to CMS, 2019-2025
16 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $38.99 · 2021: $11.73 · 2023: $61.45 · 2024: $43.98 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308 · Education: $20.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.98 |
| Education | $20.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $97.63 | 2019 | |
| Janssen Biotech, INC. | $83.94 | 2023-2025 | Darzalex, Imbruvica, Rybrevant |
| Merck Sharp & Dohme LLC | $76.00 | 2024-2025 | Keytruda |
| Alexion Pharmaceuticals, INC. | $49.62 | 2019-2020 | |
| Abbvie INC. | $39.13 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.95 | 2020-2025 | Opdivo |
| Beigene USA, INC. | $24.81 | 2025 | Brukinsa |
| Novo Nordisk INC | $22.66 | 2019 | |
| Amgen INC. | $20.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.51 | 2025 | |
| Caris Mpi, INC. | $19.14 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $16.91 | 2025 | Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $16.38 | 2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $16.38 | 2019 | |
| Insulet Corporation | $14.04 | 2025 | Omnipod |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.